Esketamine: Clinical Trials

23 trials of Esketamine, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

16 completed, 3 recruiting, 2 unknown, 1 terminated. 23 Phase 3, 5 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 323Completed 16, Recruiting 3, Unknown 2, Terminated 1, Withdrawn 1
Phase 25Completed 4, Unknown 1

Follow Esketamine: new trials by email Literature Review of Esketamine trials Research Report on Esketamine

Trials (filtered) newest first · largest first

All 23 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study of Esketamine Nasal Spray Versus Placebo Spray in Adult Participants With Treatment-resistant Depression
Esketamine 56 mg, Esketamine 84 mg, Placebo - Depressive Disorder, Treatment-Resistant
Phase 3RecruitingJanssen Research & Development, LLC3482026-07-232026-11-03
A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder
Esketamine, Midazolam, Oral Placebo - Depressive Disorder, Major
Phase 3RecruitingJanssen Research & Development, LLC2582026-01-082026-11-03
PCORI Comparative Effectiveness Study-Esketamine (Spravato) vs. Ketamine-Equivalence Study
Racemic ketamine, Spravato (Esketamine) - Depression
Phase 3RecruitingYale University4002025-01-272026-09-08
Fentanyl OR Esketamine for Traumatic PAIN (FORE-PAIN) Trial
Fentanyl Citrate, Esketamine - Acute Pain Due to Trauma, Analgesia
Phase 3TerminatedAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)2352024-01-112026-09-15
Esketamine Combined With Pregabalin on CPSP in Spinal Patients.
S-ketamine and pregabalin, Normal saline and placebo capsule - Esketamine, Pregabaline
Phase 2 / Phase 3UnknownBeijing Tiantan Hospital1502023-11-102023-11-07
The Efficacy and Safety of Esketamine in Elective Laparoscopic Surgery
BT-KTM-I, Ketanest®S - Laparoscopy, Anesthesia, Intravenous
Phase 3CompletedChengdu Brilliant Pharmaceutical Co., Ltd.3582023-09-202024-07-29
Adjunctive Esketamine for Analgesia in Mechanically Ventilated Septic Shock Patients
Esketamine, Saline, Remifentanil + propofol - Septic Shock, Mechanical Ventilation Complication
Phase 3UnknownNanfang Hospital, Southern Medical University1242023-05-312023-11-22
The Effect of Esketamine Combined With Pregabalin on Chronic Postsurgical Pain in Patients After Craniotomy.
S-ketamine and pregabalin, Normal saline and placebo capsule - Chronic Postsurgical Pain
Phase 2 / Phase 3CompletedBeijing Tiantan Hospital2462021-12-202024-08-01
Esketamine Combined With Pregabalin on Acute Postoperative Pain in Patients Undergoing Resection of Spinal Neoplasms.
S-ketamine and pregabalin, Normal saline and placebo capsule - Esketamine, Pregabalin
Phase 2 / Phase 3CompletedBeijing Tiantan Hospital902021-12-012023-07-06
Esketamine and Perioperative Depressive Symptoms
Esketamine, Normal saline - Depressive Symptoms, Esketamine
Phase 2 / Phase 3CompletedBeijing Tiantan Hospital4352021-02-192025-08-01
An Expanded Access Protocol for Esketamine Treatment in Participants With Treatment Resistant Depression (TRD) Who do Not Have Other Treatment Alternatives
Esketamine - Depression
Phase 3CompletedJanssen-Cilag, S.A.412020-09-082023-09-14
A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in Participants With Treatment Resistant Major Depressive Disorder
Esketamine 28 mg, Esketamine 56 mg, Esketamine 84 mg - Depressive Disorder, Major
Phase 3CompletedJanssen-Cilag International NV6762020-08-212025-04-29
A Study of Esketamine Nasal Spray Plus a New Standard-of-care Oral Antidepressant or Placebo Nasal Spray Plus a New Standard-of-care Oral Antidepressant in Adult and Elderly Participants With Treatment-resistant Depression
Esketamine 28 mg, Esketamine 56 mg, Esketamine 84 mg - Depressive Disorder, Treatment-Resistant
Phase 3WithdrawnJanssen-Cilag International NV2019-12-012025-04-27
A Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression
Esketamine 56 mg, Esketamine 84 mg, Placebo - Depressive Disorder, Treatment-Resistant
Phase 3CompletedJanssen Research & Development, LLC2522018-05-252025-04-29
54135419SUI3002: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Participants Assessed to be at Imminent Risk for Suicide
Esketamine, Placebo, Standard of Care - Depressive Disorder, Major
Phase 3CompletedJanssen Research & Development, LLC2302017-06-152025-04-29
54135419SUI3001: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Participants Assessed to be at Imminent Risk for Suicide
Esketamine, Placebo, Standard of Care - Depressive Disorder, Major
Phase 3CompletedJanssen Research & Development, LLC2262017-06-092025-04-29
A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression
Esketamine, Placebo, Duloxetine (Oral Antidepressant) - Depressive Disorder, Treatment-Resistant
Phase 3CompletedJanssen Research & Development, LLC7192015-10-012025-04-29
A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression
Esketamine (Intranasal Spray), Duloxetine (Oral Antidepressant), Escitalopram (Oral Antidepressant) - Treatment-resistant Depression
Phase 3CompletedJanssen Research & Development, LLC8022015-09-302025-04-29
A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression
Esketamine, Placebo, Duloxetine (Oral Antidepressant) - Depressive Disorder, Treatment-Resistant
Phase 3CompletedJanssen Research & Development, LLC1392015-08-202025-04-29
A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression
Esketamine, Placebo, Duloxetine (Oral Antidepressant) - Treatment-resistant Depression
Phase 3CompletedJanssen Research & Development, LLC3462015-08-102025-04-29

Showing 20 of 23. Sign in to see all of them.

Conditions studied

Depressive Disorder, Treatment-Resistant (8)  ·  Depressive Disorder, Major (4)  ·  Agnosia (3)  ·  Depression (3)  ·  Pain, Postoperative (3)  ·  Drug-Related Side Effects and Adverse Reactions (1)  ·  Pain (1)  ·  Shock, Septic (1)  ·  Spinal Cord Neoplasms (1)  ·  Spinal Stenosis (1)

Sponsors

Janssen Research & Development, LLC (10)  ·  Beijing Tiantan Hospital (4)  ·  Janssen-Cilag International NV (2)  ·  Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (1)  ·  Chengdu Brilliant Pharmaceutical Co., Ltd. (1)  ·  Janssen-Cilag, S.A. (1)  ·  Medical University of Graz (1)  ·  Nanfang Hospital, Southern Medical University (1)  ·  University Hospital, Basel, Switzerland (1)  ·  Yale University (1)

Countries

United States (11)  ·  China (8)  ·  Brazil (7)  ·  Spain (7)  ·  Belgium (6)  ·  Poland (6)  ·  France (5)  ·  Germany (5)  ·  Hungary (5)  ·  Taiwan (5)  ·  Austria (4)  ·  Bulgaria (4)  ·  Czechia (4)  ·  Mexico (4)  ·  South Africa (4)

Top investigators

Ruquan Han, M.D., Ph D. (3)  ·  Markus W Hollmann, Prof. dr. dr. (1)  ·  Mischa Wejbora, MD (1)  ·  Ruquan Han, M.D., Ph D (1)  ·  Samuel Wilkinson, MD (1)  ·  Wen Ouyang, MD (1)  ·  Wilhelm Ruppen, MD (1)

Results publications

PMID 32860422, PMID 34235612, PMID 34510411, PMID 33128208, PMID 35022754, PMID 38557430, PMID 32367114, PMID 34288609, PMID 34973081, PMID 35816217, PMID 35904046, PMID 36149841, PMID 36273682, PMID 37019044, PMID 37439961, PMID 37568081, PMID 39428602, PMID 31109201, PMID 31166571, PMID 31290965, PMID 32270176, PMID 32316080, PMID 32412700, PMID 32861217, PMID 34293233, PMID 34412104, PMID 34750057, PMID 35441931, PMID 35473735, PMID 36525338, PMID 36841794, PMID 37158911, PMID 37558912, PMID 37792613, PMID 38025416, PMID 38025433, PMID 38169502, PMID 38169503, PMID 38501980, PMID 38954874, PMID 39435126, PMID 40420189, PMID 41245530, PMID 41674286, PMID 42119799, PMID 42298878

NIH funding

2014 (5), 2016 (2), 2018 (1), 2019 (1)